Esophageal Cancer

Showing NaN - NaN of 67

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified

Recruiting
  • Endometrial Cancer
  • +8 more
  • Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks
  • Boston, Massachusetts
  • +20 more
Aug 23, 2022

Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in United States (ELU001)

Recruiting
  • Ovarian Cancer
  • +68 more
  • Phoenix, Arizona
  • +8 more
Aug 18, 2022

Esophageal Cancer, Esophagogastric Junction Cancer Trial in Worldwide (Autologous genetically modified ADP-A2M4CD8 cells)

Recruiting
  • Esophageal Cancer
  • Esophagogastric Junction Cancer
  • Autologous genetically modified ADP-A2M4CD8 cells
  • Duarte, California
  • +33 more
Aug 16, 2022

Intestinal Microbiome, Oral Microbiome, and Whole Blood

Recruiting
  • Gastrointestinal Cancer
  • +6 more
    • New York, New York
      Icahn School of Medicine at Mount Sinai
    Aug 5, 2022

    Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression Trial in New York, Providence (Nivolumab, Trastuzumab

    Not yet recruiting
    • Esophageal Adenocarcinoma
    • +3 more
    • New York, New York
    • +1 more
    Jul 28, 2022

    Esophagogastric Tumors, Gastric Cancer, Gastric Tumor Trial in United States (Trastuzumab, Pembrolizumab)

    Recruiting
    • Esophagogastric Tumors
    • +9 more
    • Basking Ridge, New Jersey
    • +6 more
    Jul 8, 2022

    Advanced Solid Tumor, NSCLC, Melanoma Trial in United States (AB308, Zimberelimab)

    Recruiting
    • Advanced Solid Tumor
    • +9 more
    • Phoenix, Arizona
    • +20 more
    May 2, 2022

    Esophageal Cancer, Gastric Cancer Trial in United States (Afatinib and Paclitaxel)

    Active, not recruiting
    • Esophageal Cancer
    • Gastric Cancer
    • Afatinib and Paclitaxel
    • Los Angeles, California
    • +8 more
    Mar 18, 2022

    Kidney Cancer, Head Neck Cancer, Breast Cancer Trial in New York (177Lu-J591)

    Completed
    • Kidney Cancer
    • +8 more
    • New York, New York
      Weill Cornell Medical College
    Feb 1, 2022

    Tissue & Blood From Patients w/ Benign & Malignant Tumors of

    Active, not recruiting
    • Esophageal Cancer
    • +6 more
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      Nov 12, 2021

      Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer Trial in United States (drug, procedure, radiation)

      Active, not recruiting
      • Adenocarcinoma of the Gastroesophageal Junction
      • Esophageal Cancer
      • Mountain View, California
      • +67 more
      Oct 5, 2021

      Prostate Cancer, Bladder Cancer, NSCLC Trial in New York, Houston (NY-ESO-1 Plasmid DNA Cancer Vaccine)

      Completed
      • Prostate Cancer
      • +4 more
      • NY-ESO-1 Plasmid DNA Cancer Vaccine
      • New York, New York
      • +1 more
      Sep 15, 2021

      Esophageal Cancer Trial in New York (other, device, procedure)

      Recruiting
      • Esophageal Cancer
      • Injection of indocyanine green (ICG)dye
      • +2 more
      • New York, New York
        Memorial Sloan Kettering Cancer Center (All Protocol Activities)
      Sep 29, 2021

      Clinical Management of Esophageal Adenocarcinoma (EAC)

      Active, not recruiting
      • Esophageal Cancer
      • Adenocarcinoma
      • serum and tissue mesothelin
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      Oct 1, 2021

      Esophageal Cancer Trial in United States (cetuximab, ECF, IC)

      Completed
      • Esophageal Cancer
      • cetuximab
      • +3 more
      • Norwalk, Connecticut
      • +226 more
      Sep 2, 2021

      Esophageal Cancer, Gastric Cancer Trial in United States (pembrolizumab, trastuzumab, capecitabine)

      Active, not recruiting
      • Esophageal Cancer
      • Gastric Cancer
      • Basking Ridge, New Jersey
      • +7 more
      Sep 17, 2021

      Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma Trial in United States (Sacituzumab Govitecan-hziy (SG))

      Completed
      • Gastric Adenocarcinoma
      • +15 more
      • Sacituzumab Govitecan-hziy (SG)
      • Aurora, Colorado
      • +11 more
      Aug 10, 2021

      Following Minimally Invasive and Open Esophagectomy for

      Completed
      • Esophageal Cancer
      • Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      Aug 5, 2021

      Liver Cancer, Anxiety Disorder, Depression Trial in United States (Early palliative care)

      Completed
      • Liver Cancer
      • +9 more
      • Early palliative care
      • La Jolla, California
      • +22 more
      Jul 22, 2021

      Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer Trial in Belgium, United States (INCB062079)

      Terminated
      • Hepatocellular Carcinoma (HCC)
      • +5 more
      • Birmingham, Alabama
      • +5 more
      Jul 13, 2020

      Esophageal Cancer, Gastric Cancer Trial in United States (Regorafenib, 5-Fluorouracil, Leucovorin)

      Completed
      • Esophageal Cancer
      • Gastric Cancer
      • Basking Ridge, New Jersey
      • +4 more
      May 1, 2020

      Esophageal Cancer, Gastric Cancer Trial in Canada, United States (cisplatin, epirubicin HCl, fluorouracil)

      Completed
      • Esophageal Cancer
      • Gastric Cancer
      • Anniston, Alabama
      • +534 more
      Apr 28, 2020

      Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer Trial in United States (FOLFOX regimen,

      Completed
      • Adenocarcinoma of the Gastroesophageal Junction
      • +2 more
      • FOLFOX regimen
      • +5 more
      • Mobile, Alabama
      • +507 more
      Oct 25, 2019

      Esophageal Cancer, Gastroesophageal Junction Cancer Trial in New York (Sorafenib, administered orally, CT/MRI)

      Completed
      • Esophageal Cancer
      • Gastroesophageal Junction Cancer
      • Sorafenib, administered orally
      • CT/MRI
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      Mar 13, 2019